Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of Obesity in Severe Asthma in the German Asthma Net.
Bal C, Pohl W, Milger K, Skowasch D, Schulz C, Gappa M, Koerner-Rettberg C, Jandl M, Schmidt O, Zehetmayer S, Taube C, Hamelmann E, Buhl R, Korn S, Idzko M; German Asthma Net (GAN) study group. Bal C, et al. Among authors: jandl m. J Allergy Clin Immunol Pract. 2023 Nov;11(11):3417-3424.e3. doi: 10.1016/j.jaip.2023.06.049. Epub 2023 Jul 4. J Allergy Clin Immunol Pract. 2023. PMID: 37406803
Benralizumab for the Prevention of COPD Exacerbations.
Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators. Criner GJ, et al. N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112385 Clinical Trial.
Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial.
Martinez FJ, Criner GJ, Gessner C, Jandl M, Scherbovsky F, Shinkai M, Siler TM, Vogelmeier CF, Voves R, Wedzicha JA, Bartels C, Bottoli I, Byiers S, Cardenas P, Eckert JH, Gutzwiller FS, Knorr B, Kothari M, Parlikar R, Tanase AM, Franssen FME. Martinez FJ, et al. Among authors: jandl m. Am J Respir Crit Care Med. 2023 Aug 15;208(4):417-427. doi: 10.1164/rccm.202303-0458OC. Am J Respir Crit Care Med. 2023. PMID: 37411039 Free PMC article. Clinical Trial.
Characteristics and treatment regimens across ERS SHARP severe asthma registries.
van Bragt JJMH, Adcock IM, Bel EHD, Braunstahl GJ, Ten Brinke A, Busby J, Canonica GW, Cao H, Chung KF, Csoma Z, Dahlén B, Davin E, Hansen S, Heffler E, Horvath I, Korn S, Kots M, Kuna P, Kwon N, Louis R, Plaza V, Porsbjerg C, Ramos-Barbon D, Richards LB, Škrgat S, Sont JK, Vijverberg SJH, Weersink EJM, Yasinska V, Wagers SS, Djukanovic R, Maitland-van der Zee AH; SHARP Clinical Research Collaboration; Members of the SHARP Clinical Research Collaboration are. van Bragt JJMH, et al. Eur Respir J. 2020 Jan 9;55(1):1901163. doi: 10.1183/13993003.01163-2019. Print 2020 Jan. Eur Respir J. 2020. PMID: 31601713 Free article.
Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA).
Panettieri RA Jr, Welte T, Shenoy KV, Korn S, Jandl M, Kerwin EM, Feijoo R, Barker P, Olsson RF, Martin UJ; SOLANA Study Investigators. Panettieri RA Jr, et al. Among authors: jandl m. J Asthma Allergy. 2020 Feb 17;13:115-126. doi: 10.2147/JAA.S240044. eCollection 2020. J Asthma Allergy. 2020. PMID: 32110060 Free PMC article.
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG; ANDHI study investigators. Harrison TW, et al. Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22. Lancet Respir Med. 2021. PMID: 33357499 Clinical Trial.
Bronchodilator Reversibility in the GAN Severe Asthma Cohort.
Milger K, Skowasch D, Hamelmann E, Mümmler C, Idzko M, Gappa M, Jandl M, Körner-Rettberg C, Ehmann R, Schmidt O, Taube C, Holtdirk A, Timmermann H, Buhl R, Korn S. Milger K, et al. Among authors: jandl m. J Investig Allergol Clin Immunol. 2023 Dec 14;33(6):446-456. doi: 10.18176/jiaci.0850. Epub 2022 Aug 24. J Investig Allergol Clin Immunol. 2023. PMID: 36000830 Free article.
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G; DESTINATION study investigators. Menzies-Gow A, et al. Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23. Lancet Respir Med. 2023. PMID: 36702146 Clinical Trial.
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.
Jackson DJ, Heaney LG, Humbert M, Kent BD, Shavit A, Hiljemark L, Olinger L, Cohen D, Menzies-Gow A, Korn S; SHAMAL Investigators. Jackson DJ, et al. Lancet. 2024 Jan 20;403(10423):271-281. doi: 10.1016/S0140-6736(23)02284-5. Epub 2023 Dec 7. Lancet. 2024. PMID: 38071986 Free article. Clinical Trial.
As-needed low-dose inhaled corticosteroid/formoterol therapy in patients with severe asthma included in the German Asthma Net cohort.
Hinze CA, Ehmann R, Jandl M, Milger K, Schmidt O, Schulz C, Skowasch D, Welte T, Buhl R, Hamelmann E, Idzko M, Taube C, Korn S, Suhling H. Hinze CA, et al. Among authors: jandl m. ERJ Open Res. 2024 Apr 8;10(2):00741-2023. doi: 10.1183/23120541.00741-2023. eCollection 2024 Mar. ERJ Open Res. 2024. PMID: 38590938 Free PMC article.
39 results